Sign in Create account

Anthem Biosciences Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: ANTHEM BSE: 544449
₹858.60
▼ -11.15 (-1.28%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
73/100
Strong
Valuation
—/100
Expensive
Momentum
30/100
Neutral

QVM read Quality business Quality Strong, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹48,372 Cr
PE (TTM)
77.2
Industry median 36.1 (152 companies)
Price to Book
15.9
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
16.06%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
18.2
Relative return vs Sector, qtr %
12.5
Free Cash Flow
₹633 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-31.70%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
Data unavailable.
Operating Revenue Growth (TTM)
Data unavailable.
Profit Growth (YoY)
-31.23%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-28.66%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
5.54
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.02
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
148.33
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
26.58%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
35.72%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
43.73%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
17.26%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
26.78%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
19.45%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 4 met
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.02)
  • Yes Return on equity is 15% or more (19.5%)
  • Yes Net cash flow for the latest year is positive

Ownership

3 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • No Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

0 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.3%
Low 855.0500 · High 878.2000
1W return
-2.6%
Low 849.0000 · High 898.5500
1M return
-3.9%
Low 849.0000 · High 977.5500
52W return
11.4%
Low 579.1500 · High 977.5500
Lifetime High ₹957.8000 (Sept. 8, 2026)
Lifetime Low ₹587.8500 (Feb. 1, 2026)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish2
Bearish4
5D
869.1
10D
883.3
20D
894.2
50D
874.5
100D
830.2
200D
748.5

Delivery and volume

Day avg. delivery
64.8%
Week avg. delivery
57.3%
Month avg. delivery
59.2%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

863.95
Pivot
First resistance872.85
Second resistance887.10
Third resistance896.00
First support849.70
Second support840.80
Third support826.55
Day RSI40.1
Day MFI57.3
Day MACD-6.08
Day MACD signal5.05

Beta

1M-0.14
3M0.52
1Y0.55
3Y0.66

Price change analysis

↓ -3.9%
Over 1 Month
LowHigh
849.00977.55
↑ 12.5%
Over 3 Months
LowHigh
732.00977.55
↑ 29.0%
Over 6 Months
LowHigh
648.25977.55
↑ 11.4%
Over 1 Year
LowHigh
579.15977.55
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 77.2 (own history: 54.9–69.3)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹384 Cr
Net profit (June 30, 2026)
₹102 Cr
Basic EPS (June 30, 2026)
₹1.8100

Ranks #16 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter71.42%
  • Mutual funds11.15%
  • FII/FPI2.58%
  • Other DII2.33%
  • Public12.52%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings decreased from 74.68% to 71.42% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 1.28% to 2.58% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 10.12% to 11.15% in Jun 2026 qtr

38 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 3 insider trades, 1 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
12 Mar 2026 Aruna Ganesh Promoter group Buy 0 ₹0
12 Mar 2026 Krithika Ganesh Promoter group Sell 0 ₹0
12 Mar 2026 Viridity Tone LLP Other Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 67 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
18 Jun 2026 WHITEOAK CAPITAL MUTUAL FUND Block Buy 262,661 744.8000 NSE
18 Jun 2026 WHITEOAK CAPITAL MUTUAL FUND Block Buy 18,635 744.8000 NSE
18 Jun 2026 WHITEOAK CAPITAL MUTUAL FUND Block Buy 61,318 744.8000 NSE
18 Jun 2026 WHITEOAK CAPITAL MUTUAL FUND Block Buy 100,458 744.8000 NSE
18 Jun 2026 UTI MUTUAL FUND Block Buy 760,538 744.8000 NSE
18 Jun 2026 UTI MUTUAL FUND Block Buy 49,728 744.8000 NSE
18 Jun 2026 UTI MUTUAL FUND Block Buy 532,377 744.8000 NSE
18 Jun 2026 SOCIETE GENERALE Block Buy 335,661 744.8000 NSE
18 Jun 2026 SOCIAL PROTECTION FUND Block Buy 44,056 744.8000 NSE
18 Jun 2026 SBI MUTUAL FUND Block Buy 240,000 744.8000 NSE

All bulk and block deals →

Dividends

Full dividend history →
Last 12 months ₹2.00 per share
Dividend yield 0.23%
Ex-dateSubjectPer share (₹)Record date
25 Jun 2026 Dividend - Rs 2 Per Share 2.0000 26 Jun 2026

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
21 Jul 2026 Financial Results Yes
19 May 2026 Financial Results/Dividend Yes
5 Feb 2026 Financial Results Yes
8 Nov 2025 Financial Results Yes
13 Aug 2025 Financial Results Yes

Corporate Announcements

All 92 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
24 Sep 2026 Trading Window Anthem Biosciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
8 Sep 2026 Updates Anthem Biosciences Limited has informed the Exchange regarding 'Settlement of Upside Sharing Arrangement '.
27 Jul 2026 Analysts/Institutional Investor Meet/Con. Call Updates Anthem Biosciences Limited has informed the Exchange about Transcript
24 Jul 2026 Shareholders meeting Anthem Biosciences Limited has submitted the Exchange the voting results and a copy Srutinizers report of the 20th Annual General Meeting held on July 22, 2026.
22 Jul 2026 Shareholders meeting Anthem Biosciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 22, 2026
22 Jul 2026 Analysts/Institutional Investor Meet/Con. Call Updates Anthem Biosciences Limited has informed the Exchange about Link of Recording
22 Jul 2026 Copy of Newspaper Publication Anthem Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
21 Jul 2026 Press Release (Revised) Anthem Biosciences Limited has informed the Exchange regarding a revised press release dated July 21, 2026, titled "Press Release on Unaudited Financial Results for the Quarter ended June 30, 2026".
21 Jul 2026 Investor Presentation Anthem Biosciences Limited has informed the Exchange about Investor Presentation
21 Jul 2026 Press Release Anthem Biosciences Limited has informed the Exchange regarding a press release dated July 21, 2026, titled "Press Release on the Unaudited Financial Results for the quarter ended June 30, 2026".

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (26.6%)
  • Low financial leverage (Debt/Equity 0.02)
  • Comfortable interest coverage (148.3x)

Weaknesses

  • Declining revenue YoY (-28.7%)
  • Declining profit YoY (-31.2%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (77.2) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Part of: NIFTY 500, NIFTY 500, NIFTY MIDCAP 150, NIFTY MIDCAP 150

Frequently asked questions about Anthem Biosciences Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.